SAN DIEGO, Nov. 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will host investors and analysts in New York City on December 5, 2011 for a corporate overview and update with a focus on its commercial strategy and launch of DIFICID. A live webcast of the event will begin at 8:30 a.m. Eastern time and will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.
Speakers will include members of the executive management team as well as guest speaker Roy F. Chemaly, M.D., MPH, University of Texas MD Anderson Cancer Center.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer is seeking marketing authorization for fidaxomicin in the European Union and Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
Jason I. Spark, Senior Vice President
SOURCE Optimer Pharmaceuticals, Inc.